People / Brooke Cohen Parker
Brooke Cohen

Brooke Cohen Parker

Brooke Cohen Parker’s practice spans nearly every facet of patent law. She leverages her background in chemical and biomedical engineering to provide excellent service to clients in a wide variety of technological fields. 

Brooke obtains patents for clients in the United States and in foreign jurisdictions across the world. She is experienced prosecuting patents covering many different technologies, including medical devices, medical imaging technologies, artificial intelligence in the life sciences field, software, chemicals, and mechanical systems. 

Moreover, Brooke both defends clients’ patents and asserts the invalidity of their competitors' patents in post-grant proceedings before the Patent Trial and Appeals Board. Brooke also represents clients’ interests against infringement allegations in district court.

Further, Brooke counsels clients on patent-related topics so that they can protect their inventions against competitors and minimize the infringement risk associated with their products. She provides non-infringement, invalidity, and patentability opinions for clients at any point in their product development and commercialization processes. Brooke also provides patent landscape and portfolio analyses for clients’ for mergers or acquisitions. 

Show More
Expand All


J.D., The University of Texas School of Law, 2021

M.E., Biomedical Engineering, Texas A&M University, 2018

B.S., Chemical and Biomolecular Engineering, Cornell University, 2017, cum laude


Intern to the Honorable Judge Lee Yeakel, United States District Court, Western District of Texas, 2020



U.S. Patent and Trademark Office

McCombs, Goryunov, Cohen and Blikshteyn in Law360: ‘Amgen Patent Ruling's Impact Extends Beyond Life [...]
September 13, 2023

Haynes and Boone, LLP Lawyers David McCombs, Eugene Goryunov, Brooke Cohen and Dina Blikshteyn authored an article in Law360 on the U.S. Supreme Court’s decision in Amgen Inc. v. Sanofi that further clarified the patent enablement requirement. Read an excerpt below: In Amgen Inc. v. Sanofi, the U.S. Supreme Court in May further clarified the patent enablement requirement. At issue in the case were [...]